A chlorin compound, and a preparation and use thereof, related to medicine. The chlorin compound is represented by formula (I), or a salt, a stereisomer, a hydrate, a solvate or a prodrug thereof. ##STR00001##

Novel dinuclear silver(I) pyrazolido complexes and methods of synthesizing them are provided. Advantageously, the novel silver(I) pyrazolido complexes have excellent antimicrobial activity and methods of using said complexes to treat bacterial, fungal, and viral infections are also provided.

The present invention relates to compounds, compositions, methods of forming/preparing such compounds and compositions, and uses for sanitising and/or substantially removing biofilms and microorganisms living within or around biofilms. The present invention, in particular, relates to compounds of formula Mn(P) as described herein which can be used in wound treatments, wound dressings, medical devices, water treatments, food processing and dental care biofilms.

An especially robust compound and its derivative metal complexes that are approximately one hundred-fold superior in catalytic performance to the previously invented TAML analogs is provided having the formula (I) wherein Y.sub.1, Y.sub.2, Y.sub.3 and Y.sub.4 are oxidation resistant groups which are the same or different and which form 5- or 6-membered rings with a metal, M, when bound to D; at least one Y incorporates a group that is significantly more stable towards nucleophilic attack than the organic amides of TAML activators; D is a metal complexing donor atom, preferably N; each X is a position for addition of a labile Lewis acidic substituent such as (i) H, deuterium, (ii) Li, Na, K, alkali metals, (iii) alkaline earth metals, transition metals, rare earth metals, which may be bound to one or more than one D, (iv) or is unoccupied with the resulting negative charge being balanced by a nonbonded counter-action; at least one Y may contain a site that is labile to acid dissociation, providing a mechanism for shortening complex lifetime. The new complexes deliver catalytic performances that promise to revolutionize multiple oxidation technology spaces including water purification. ##STR00001##

The present invention relates to an adduct comprising metal particles and an adduct between an sp2 carbon allotrope and a pyrrole compound. In particular, the invention relates to an adduct comprising metal nanoparticles (NPs) and hydrophylic adducts between a sp2 carbon allotrope and a pyrrole compound. The metal preferentially copper, silver or gold. Such adduct is preferentially used for anti-bacterial activity.

An organic light-emitting device, comprising: a first electrode; a second electrode; and an organic layer located between the first electrode and the second electrode, wherein the organic layer comprises an emission layer, wherein the emission layer comprises a host, a sensitizer, and an emitter, wherein the host, the sensitizer, and the emitter are different from each other, and wherein the sensitizer is represented by Formula 1:

M.sub.1(L.sub.1)(L.sub.2)  Formula 1

wherein, in Formula 1, M.sub.1 is Au, Ag, or Cu, L.sub.1 is a ligand represented by Formula 2-1 or Formula 2-2, and L.sub.2 is a ligand represented by one of Formulae 3-1, 3-2, or 3-3:

##STR00001##

wherein A.sub.21, A.sub.31, A.sub.32, X.sub.31, R.sub.21 to R.sub.24, R.sub.31 to R.sub.35, b23, and b33 are as defined herein, and * indicates a binding site to M.sub.1 in Formula 1.

Basic copper gluconate having a formula of C.sub.6H.sub.12CuO.sub.8—X H.sub.2O and the structure of: ##STR00001## The basic copper gluconate has a theoretical copper content of 23.1% (anhydrous).

Hydroxycitric acid-metal heterocyclic compounds with covalent characteristics are provided. The subject hydroxycitric acid compounds include monomeric hydroxycitric acid (HCA) compounds having a divalent metal, lactone forms thereof, and dimeric compound forms thereof. The monomeric HCA compound includes a divalent metal (X) bonded via a 5-membered ring to both the carboxylic acid and the hydroxy group of the central C2 carbon of the HCA. In addition, a monovalent metal (Y) can also be bonded to the carboxylic acid of C3 or C1, or to both C1 and C3. The subject dimeric compounds include monomeric HCA compounds linked via a second divalent metal (X) to a carboxylic acid group of each HCA unit at C3 or C1. Also provided are compositions including a monomeric HCA compound and one or more other additional compounds. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided.

Flow batteries can include a first half-cell containing a first aqueous electrolyte solution. a second half-cell containing a second aqueous electrolyte solution, and a separator disposed between the first half-cell and the second half-cell. The first aqueous electrolyte solution contains a first redox-active material, and the second aqueous electrolyte solution contains a second redox-active material. At least one of the first redox-active material and the second redox-active material is a nitroxide compound or a salt thereof. Particular nitroxide compounds can include a doubly bonded oxygen contained in a ring bearing the nitroxide group, a doubly bonded oxygen appended to a ring bearing the nitroxide group, sulfate or phosphate groups appended to a ring bearing the nitroxide group, various heterocyclic rings bearing the nitroxide group, or acyclic nitroxide compounds.

The invention relates to a process for producing a crystalline A/M/X material, which crystalline A/M/X material comprises a compound of formula [A].sub.a[M].sub.b[X].sub.c wherein: [A] comprises one or more A cations; [M] comprises one or more M cations which are metal or metalloid cations; [X] comprises one or more X anions; a is a number from 1 to 6; b is a number from 1 to 6; and c is a number from 1 to 18. The process is capable of producing crystalline A/M/X materials while precisely controlling their stoichiometry, leading to products with finely tunable optical properties such as peak emission wavelength. The invention also relates to process for producing a thin film comprising the crystalline A/M/X material of the invention, and to a thin film obtainable by the process of the invention. An optoelectronic device comprising the thin film is also provided.